Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shun Fu Lee

Showing results (11-20 of 78) with videos related to

Pageof 8
Sort By:
Journal of Clinical Epidemiology|February 9, 2021
Patient reported outcome measures in clinical trials should be initially analyzed as continuous outcomes for statistical significance and responder analyses should be reserved as secondary analysesDavid Collister, Shrikant Bangdiwala, Michael Walsh, et al.
Diabetes, Obesity & Metabolism|May 15, 2024
Determinants of serious health outcome-free status in middle-aged and older people with dysglycaemia: Exploratory analysis of the ORIGIN trialKamel Mohammedi, Sibylle Hess, Matthew McQueen, et al.
Cardiovascular Research|March 7, 2020
Variations in incidence of venous thromboembolism in low-, middle-, and high-income countriesDeborah M Siegal, John W Eikelboom, Shun Fu Lee, et al.
Diabetes & Vascular Disease Research|March 23, 2021
Testosterone and sex hormone-binding globulin in dysglycemic women at high cardiovascular risk: A report from the Outcome Reduction with an Initial Glargine Intervention trialAnne Wang, Hertzel C Gerstein, Shun Fu Lee, et al.
Canadian Journal of Diabetes|August 6, 2025
Can a Combined Epigenetic-Biomarker Score Supplant Chronologic Age as an Independent Determinant of Incident Death in Adults with DysglycemiaHertzel C Gerstein, Guillaume Pare, Keyun Zhou, et al.
The Annals of Thoracic Surgery|August 25, 2024
Secondary Conduits in Coronary Artery Bypass Grafting SurgeryAustin Browne, Shun Fu Lee, Fraser Rubens, et al.
Diabetes & Vascular Disease Research|April 14, 2017
The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trialAslak Rautio, Kurt Boman, Hertzel C Gerstein, et al.
Diabetes Care|November 16, 2019
Novel Biomarkers for Change in Renal Function in People With DysglycemiaHertzel C Gerstein, Guillaume Paré, Matthew J McQueen, et al.
European Journal of Heart Failure|February 2, 2024
Effect of a transitional care model following hospitalization for heart failure: 3-year outcomes of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) randomized controlled trialTauben Averbuch, Shun Fu Lee, Brandon Zagorski, et al.
European Journal of Preventive Cardiology|December 21, 2018
Testosterone, sex hormone-binding globulin and risk of cardiovascular events: A report from the Outcome Reduction with an Initial Glargine Intervention trialAnne Wang, Stefan Arver, Kurt Boman, et al.
Pageof 8

Showing results (11-20 of 78) with videos related to

Sort By:
Pageof 8
Journal of Clinical Epidemiology|February 9, 2021
Patient reported outcome measures in clinical trials should be initially analyzed as continuous outcomes for statistical significance and responder analyses should be reserved as secondary analysesDavid Collister, Shrikant Bangdiwala, Michael Walsh, et al.
Diabetes, Obesity & Metabolism|May 15, 2024
Determinants of serious health outcome-free status in middle-aged and older people with dysglycaemia: Exploratory analysis of the ORIGIN trialKamel Mohammedi, Sibylle Hess, Matthew McQueen, et al.
Cardiovascular Research|March 7, 2020
Variations in incidence of venous thromboembolism in low-, middle-, and high-income countriesDeborah M Siegal, John W Eikelboom, Shun Fu Lee, et al.
Diabetes & Vascular Disease Research|March 23, 2021
Testosterone and sex hormone-binding globulin in dysglycemic women at high cardiovascular risk: A report from the Outcome Reduction with an Initial Glargine Intervention trialAnne Wang, Hertzel C Gerstein, Shun Fu Lee, et al.
Canadian Journal of Diabetes|August 6, 2025
Can a Combined Epigenetic-Biomarker Score Supplant Chronologic Age as an Independent Determinant of Incident Death in Adults with DysglycemiaHertzel C Gerstein, Guillaume Pare, Keyun Zhou, et al.
The Annals of Thoracic Surgery|August 25, 2024
Secondary Conduits in Coronary Artery Bypass Grafting SurgeryAustin Browne, Shun Fu Lee, Fraser Rubens, et al.
Diabetes & Vascular Disease Research|April 14, 2017
The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trialAslak Rautio, Kurt Boman, Hertzel C Gerstein, et al.
Diabetes Care|November 16, 2019
Novel Biomarkers for Change in Renal Function in People With DysglycemiaHertzel C Gerstein, Guillaume Paré, Matthew J McQueen, et al.
European Journal of Heart Failure|February 2, 2024
Effect of a transitional care model following hospitalization for heart failure: 3-year outcomes of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) randomized controlled trialTauben Averbuch, Shun Fu Lee, Brandon Zagorski, et al.
European Journal of Preventive Cardiology|December 21, 2018
Testosterone, sex hormone-binding globulin and risk of cardiovascular events: A report from the Outcome Reduction with an Initial Glargine Intervention trialAnne Wang, Stefan Arver, Kurt Boman, et al.
Pageof 8